GH Research reports second quarter 2026 financial results and advances inhaled mebufotenin programs in treatment-resistant depression and bipolar II disorder

GH Research reports second quarter 2026 financial results alongside progress in its clinical development pipeline built around inhaled mebufotenin. The company centers its work on treatment-resistant depression and bipolar II disorder, with program updates tied to psychiatric drug development and corporate operations. Clinical progress appears alongside standard public company disclosures such as cash position, operating results, and research spending. The core significance lies in how financial runway and trial execution interact: balance-sheet strength affects how quickly the company can move candidate treatments through studies, expand enrollment, and generate data relevant to efficacy, safety, and regulatory planning. GH Research sits within the broader psychedelic biotech sector, where investor communications often link quarterly performance to milestones in novel mental health therapeutics. Mebufotenin remains the central substance because its clinical development underpins both the scientific story and the company valuation narrative.